Clinical Study of Multi-mode Thermal Ablation for the Treatment of Pancreatic Cancer With Liver Metastasis
Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.
Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy.
Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.
- EligibilityCriteria: Inclusion Criteria:  age 18-70 years old, gender is not limited; Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver; Imaging evaluable tumors with safe access to puncture; The number of half liver tumors ≤3 and the size of each tumor ≤3 cm; ECOG PS score ≤2 points, expected survival > 3 months.  Exclusion Criteria:  Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice; The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume; Expected survival < 3 months; serious heart, lung, liver and kidney dysfunction and coagulation dysfunction; Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study; refractory ascites, pleural fluid or bad fluid; Pregnancy or breastfeeding; The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult